PARENTERAL ANTIBIOTIC USAGE PATTERNS AND EFFECTS OF INTRAVENOUS TO ORAL SWITCHING ON THE LENGTH AND COST OF HOSPITALIZATION

  • Rengganis Pranandari Department of Clinical Pharmacy, Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia.
  • Sudibyo Supardi Centre of Public Health Intervention Technology, Agency for Health Research and Development, Ministry of Health, Indonesia.
  • Retnosari Andrajati Department of Clinical Pharmacy, Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia.

Abstract

Objective: The prolonged use of intravenous antibiotics might increase the length and cost of hospitalization. The research objective, therefore, was to
evaluate the effect of switching antibiotics on the length of hospital stay and hospitalization cost. The prospective cohort research design was adopted.
The inclusion criteria were in patients who had received intravenous antibiotics.
Methods: The sample comprised 39 patients who switched antibiotics as an exposed group and 39 patients who did not switch as an unexposed
group. The data were collected using the patient medical records and the financial data from the hospital information system. The Mann–Whitney test
and Chi-square or Fisher’s exact test was applied in the analysis.
Results: The results revealed that the antibiotics most commonly switched were intravenous ceftriaxone (83.3%) and oral cefixime (94.8%). From the
five switching patterns observed, the most common switch was from intravenous ceftriaxone to oral cefixime in patients with acute gastroenteritis.
All antibiotics were administered in accordance with the National Formulary (NF) guidelines. Only metronidazole (5 mg/ml dose) was inconsistent
with NF. Switching antibiotics did not impact the length of hospital stay and hospitalization cost; however, comorbidities did have an influence here.
Conclusions: Further, switching antibiotics impacted the duration over which intravenous antibiotics were administered and the cost of antibiotics.

Keywords: Switching antibiotics, Length of stay, Cost.

References

1. Peraturan Menteri Kesehatan RI No. 2406/Menkes/Per/XII/2011.
Tentang Pedoman Umum Penggunaan Antibiotik.
2. Hadinegoro SR, Tumbelaka AR, Satari HI. Pengobatan cefixime pada
demam tifoid anak. Sari Pediatr 2001;2(4):182-7.
3. Abasaeed AE, Vlcek J, Abuelkhair MA, Andrajati R, Elnour AA.
A comparative study between prescribed and over-the-counter
antibiotics. Saudi Med J 2013;34(10):1048-54.
4. Oosterheert JJ, Bonten MJ, Schneider MM, Buskens E, Lammers JW,
Hustinx WM, et al. Effectiveness of early switch from intravenous to
oral antibiotics in severe community acquired pneumonia: Multicentre
randomised trial. BMJ 2006;333(7580):1193.
5. McLaughlin CM, Bodasing N, Boyter AC, Fenelon C, Fox JG,
Seaton RA. Pharmacy-implemented guidelines on switching
from intravenous to oral antibiotics: An intervention study. QJM
2005;98(10):745-52.
6. Shrayteh ZM, Rahal MK, Malaeb DN. Practice of switch from
intravenous to oral antibiotics. Springerplus 2014;3:717.
7. Ho BP, Lau TT, Balen RM, Naumann TL, Jewesson PJ. The impact of a
pharmacist-managed dosage form conversion service on ciprofloxacin
usage at a major Canadian teaching hospital: A pre-and post-intervention
study. BMC Health Serv Res 2005;5:48.
8. Rhew DC, Tu GS, Ofman J, Henning JM, Richards MS, Weingarten SR.
Table 7: The effect of confounding variables on the length of
hospitalization and cost of treatment
Variables n Mean Standard
deviation
p
Length of
hospitalization (days)
Age
Adult 65 5.69~6 2.24 0.591
Elderly 13 5.92~6 2.18
BMI
Underweight 11 5.91~6 2.62 0.907
Not underweight 67 5.70~6 2.17
Comorbidity
Present 69 6.01~6 2.19 0.000
None 9 3.56~4 0.73
Payment methods
Assurance 63 5.95~6 2.29 0.052
Non‑assurance 15 4.80~5 1.66
Cost (rupiah)
Age
Adult 65 2621.780 1849.116 0.433
Elderly 13 2832.572 1408.100
BMI
Underweight 11 2806.242 1621.443 0.651
Not underweight 67 2632.396 1811.281
Comorbidity
Present 69 2874.471 1774.747 0.000
None 9 988.959 278.168
Payment methods
Assurance 63 2739.944 1679.054 0.109
Non‑assurance 15 2308.181 2172.142
BMI: Body mass index
Table 8: Effect of switching on the length of stay and cost of
treatment
Variables n Mean Standard
deviation
p
Length (day)
Switching group 39 5.56~6 2.1 0.619
Non‑switching group 39 5.89~6 2.35
Cost (rupiah)
Switching group 39 2400.980 1340.565 0.475
Non‑switching group 39 2912.844 2113.276
Table 9: Relationship between independent variables,
dependent variables, and confounding variables with respect to
patients’ treatment
Variables B Beta p R2
Duration
Comorbidity –2.422 –0.351 0.001 0.165
Payment status –1.099 –0.196 0.067
Cost
Antibiotic switching 66,6563.58 0.189 0.082 0.152
Comorbidity –2.011 –0.364 0.001
be discharged as soon as their clinical condition is stable, they present no
active medical problems, and have a safe environment in which to continue
therapy [19]. Switching can also reduce the cost of antibiotics significantly
but does not reduce hospitalization costs. This is due to the presence of
comorbidities. Thus, even though the cost of antibiotics is reduced, other
drug costs are still incurred through actions, support, and treatments taken
to combat the comorbidities. The results of this study are consistent with
some previous works. For example, according to a study in Switzerland [9],
the use of checklists as a reminder of the criteria for intravenous oral
antibiotic switching may significantly reduce the duration of intravenous
antibiotics. However, the decrease in the length of hospitalization was
not found to be statistically significant. A retrospective observational
study in Lebanon [6] reported that the duration of intravenous antibiotics
administered in the switching group was shorter than that in the nonswitching
group. The length of hospitalization in the switching group was
shorter than in the switching group, but these results were not significant
either. Different results were found in a study on antibiotic switching in
severe community-acquired pneumonia patients in the Netherlands. The
study reported that switching antibiotics can significantly reduce the
duration of intravenous administration and the length of hospitalization.
Suggestions for further research include the need to examine the role
of clinical pharmacists in intravenous to oral switching of antibiotics
Table 10: The effects of switching against the length and cost of
using antibiotics among patients
Variables n Mean Standard
deviation
p
Duration (day)
Switching group 39 3.49 1.19 0.000
Non‑switching group 39 5.67 2.33
Cost (rupiah)
Switching group 39 46.478 51.947 0.003
Non‑switching group 39 114.781 169.660
89
Int J App Pharm, Special Issue (October)
Pranandari et al.
Early switch and early discharge strategies in patients with
community-acquired pneumonia: A meta-analysis. Arch Intern Med
2001;161(5):722-7.
9. Di Giammarino L, Bihl F, Bissig M, Bernasconi B, Cerny A,
Bernasconi E. Evaluation of prescription practices of antibiotics in a
medium-sized Swiss hospital. Swiss Med Wkly 2005;135(47-48):710-4.
10. Dunn K, O’Reilly A, Silke B, Rogers T, Bergin C. Implementing a
pharmacist-led sequential antimicrobial therapy strategy: A controlled
before-and-after study. Int J Clin Pharm 2011;33(2):208-14.
11. Davis SL, Delgado G, McKinnon PS. Pharmacoeconomic
considerations associated with the use of intravenous-to-oral
moxifloxacin for community-acquired pneumonia. Clin Infect Dis
2005;41 Suppl 2:S136-43.
12. RSUD Kota Depok. Buku Profil RSUD Kota Depok 2013. Depok:
RSUD Kota Depok; 2013.
13. Almatsier S, Soetardjo S, Soekatri M. Gizi Seimbang Dalam Daur
Kehidupan. Jakarta: Gramedia Pustaka Utama; 2011.
14. Low S, Chin MC, Ma S, Heng D, Deurenberg-Yap M. Rationale for
redefining obesity in Asians. Ann Acad Med Singapore 2009;38(1):66-9.
15. Mertz D, Koller M, Haller P, Lampert ML, Plagge H, Hug B, et al.
Outcomes of early switching from intravenous to oral antibiotics on
medical wards. J Antimicrob Chemother 2009;64(1):188-99.
16. Senn L, Burnand B, Francioli P, Zanetti G. Improving appropriateness
of antibiotic therapy: Randomized trial of an intervention to foster
reassessment of prescription after 3 days. J Antimicrob Chemother
2004;53(6):1062-7.
17. Kuwabara K, Imanaka Y, Matsuda S, Fushimi K, Hashimoto H,
Ishikawa KB, et al. The association of the number of comorbidities
and complications with length of stay, hospital mortality and LOS
high outlier, based on administrative data. Environ Health Prev Med
2008;13(3):130-7.
18. Lestari W. Studi Penggunaan Antibiotik berdasarkan Sistem ATC/DDD
dan Kriteria Gyysens di Bangsal Penyakit Dalam RSUP DR.M.D Jamil
Padang [Thesis]. Padang: Universitas Andalas; 2011.
19. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD,
Dean NC, et al. Infectious Diseases Society of America/American
Thoracic Society consensus guidelines on the management
of community-acquired pneumonia in adults. Clin Infect Dis
2007;44 Suppl 2:S27-72.
Statistics
162 Views | 156 Downloads
How to Cite
Pranandari, R., Supardi, S., & Andrajati, R. (2017). PARENTERAL ANTIBIOTIC USAGE PATTERNS AND EFFECTS OF INTRAVENOUS TO ORAL SWITCHING ON THE LENGTH AND COST OF HOSPITALIZATION. International Journal of Applied Pharmaceutics, 9, 85-89. https://doi.org/10.22159/ijap.2017.v9s1.44_50
Section
Original Article(s)